ReviewNeuropharmacology2019
Development of vaccines to treat opioid use disorders and reduce incidence of overdose.
Review in Neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 85 citations in OpenAlex.
- Novel Swine Model of Respiratory Depression Induced by Fentanyl and Heroin Overdose.Research square · 2026Article
- Precision Adjuvant Strategies in Vaccine Development for Substance Use Disorders: Variability and Mechanistic Insights.Pharmaceutics · 2025Review
- A novel cationic liposome-formulated toll like receptor (TLR) 7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Bivalent Hapten Display Strategies for Conjugate Vaccines Targeting Opioid Mixtures Containing Fentanyl.Bioconjugate chemistry · 2025Article
- Two doses of Qβ virus like particle vaccines elicit protective antibodies against heroin and fentanyl.NPJ vaccines · 2025Article
- Product and trial design considerations on the path towards a vaccine to combat opioid overdose.NPJ vaccines · 2025Review
- The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention.The international journal of neuropsychopharmacology · 2025Review
- The immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines.Biomaterials · 2025Article
- Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment options.Pharmacology, biochemistry, and behavior · 2024Review
- Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Opioid-Based Haptens: Development of Immunotherapy.International journal of molecular sciences · 2024Review
- Enhancing Protective Antibodies against Opioids through Antigen Display on Virus-like Particles.Bioconjugate chemistry · 2024Article
- Multivalent Vaccination Strategies Protect against Exposure to Polydrug Opioid and Stimulant Mixtures in Mice and Rats.ACS pharmacology & translational science · 2024Article
- Daily methocinnamox treatment dose-dependently attenuates fentanyl self-administration in rhesus monkeys.Neuropharmacology · 2024Article
- Article
- Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments.Pharmacological reviews · 2023Review
- Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge.Bioconjugate chemistry · 2023Article
- A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models.NPJ vaccines · 2023Article
- Chemical tools for the opioids.Molecular and cellular neurosciences · 2023Review
- IL-4 Predicts the Efficacy of a Candidate Antioxycodone Vaccine and Alters Vaccine-Specific Antibody-Secreting Cell Proliferation in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Vaccines offer a promising therapeutic strategy to treat substance use disorders (SUD). Vaccines have shown extensive preclinical proof of selectivity, safety, and efficacy against opioids, nicotine, cocaine, methamphetamine, and designer drugs. Despite clinical evaluation of vaccines targeting nicotine and cocaine showing proof of concept for this approach, no vaccine for SUD has yet reached the market. This review first discusses how vaccines for treatment of opioid use disorders (OUD) and reduction of opioid-induced fatal overdoses fit within the current medication assisted treatment (MAT) portfolio, and then summarizes ongoing efforts toward translation of vaccines targeting heroin, oxycodone, fentanyl, and other opioids. This article is part of the Special Issue entitled 'New Vistas in Opioid Pharmacology'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.